Abbas Kinbar Kuser, Sagban Marja Tarar, Omar Mansib Kassid, Nael Hussein Zayer
Abbas Kinbar Kuser1*, Sagban Marja Tarar2, Omar Mansib Kassid3, Nael Hussein Zayer4
1,3College of Medicine, University of Misan, Iraq.
2Otolaryngology CABS, Iraq.
4Al-Sadder Teaching Hospital, Iraq.
Volume - 13,
Issue - 12,
Year - 2020
Background: At the end of the year 2019 and exactly in December, several unsolved pneumonia suitcases happened in Wuhan, China and has quickly feast to further shares of the Chinese area, formerly to (EU, USA, and Asia). The outburst was established designate affected by a novel coronavirus. Aim of the study: to determine neurological symptoms of patients suffering from COVID-19. Patients and Methods: One hundred and seven patients attended to the research laboratory established severe acute respiratory syndrome from coronavirus infection. Information we remembered from 30 January 2020 to 21 March 26, 2020. Medical information was taken from electrical medicinal archives and studied by a skilled group of medical doctors. Neurological indicators descent into three groups: (1) diseases of the central nervous system (headache; dizziness; acute cerebrovascular disease; impaired consciousness; ataxia; and epilepsy) (2) signs and symptoms of the Peripheral nervous system (hypogeusia; hyposmia; hypoplasia; and neuralgia) (3) And symptoms of skeletal muscles. The neurologists were rechecked all Information of all neurological symptoms. Results: 107 patients deliberate, 44 (41.10%) were severe and 63 (58.90%) were mild patients. Matched with mild and severe patients were elder (58.70±15.00 years vs 48.90±14.70 years) ,had extra fundamental illnesses (42 [47.70%] vs 41 [32.50%]) , particularly HTN (16 [36.40%] vs 9 [15.10%]) , and exhibited a smaller amount characteristic indicators for example fever (20[45.50%] vs 46 [73.0%]) and cough (15[34.10%] vs 38 [61.10%]). Thirty-nine (36.40%) patients with symptoms of neurologic appearance. Additionally, severe patients with neurologic manifestations (20 [45.50%] vs 19 [30.20%]), for example CVA illness (3[5.70%] vs 1 [0.80%]), diminished awareness (6 [14.80%] vs 1[2.40%]) and injury of skeletal muscle (8[19.30%] vs 3[4.80%]). Conclusion: Matched with mild patients suffering from coronavirus; severe patients had neurologic manifestation established as acute CVA, awareness diminishing, and skeletal muscle manifestations.
Cite this article:
Abbas Kinbar Kuser, Sagban Marja Tarar, Omar Mansib Kassid, Nael Hussein Zayer. CNS and COVID-19: Neurological symptoms of Hospitalized Patients with Coronavirus in Iraq: a surveying case sequences study. Research J. Pharm. and Tech. 2020; 13(12):6291-6294. doi: 10.5958/0974-360X.2020.01094.X
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China. N Engl J Med 2020; 20:382-8. doi:10.1056/NEJMoa2001017
2. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; published online 3 February. doi:10.1038/s41586-020-2012-7
3. Zhao Y, Zhao Z, Wang Y, et al. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv 2020, published online 26 January. doi: 10.1101/2020.01.26.919985.
4. WHO. Coronavirus disease 2019 (COVID-19) Situation Report-32. January, 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200221-sitrep-32-covid-19.pdf?sfvrsn=4802d089_2 (accessed Feb 21, 2020).
5. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol 2016; 24:490-502. doi:10.1016/j.tim.2016.03.003
6. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). November, 2019. https://www.who.int/emergencies/mers-cov/en/ (accessed Jan 19, 2020).
7. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv 2020, published online 9 February. doi:10.1101/2020.02.06.20020974.
8. WHO. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance. January, 2020. https://www.who.int/internal-publications-detail/clinical-management- of-severeacute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected (accessed February 5, 2020)
9. Huang C, Wang Y, Li X, et al. Clinical features of patients with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 10223:497-506. doi: 10.1016/S0140- 6736(20)30183-5
10. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia: An official clinical practice guideline of the American Thoracic Society and Infectious Disease Society of America. Am J Respir Crit Care Med 2019; 200:e45-e67. doi:10.1164/rccm.201908-1581ST
11. Hamming, W Timens, MLC Bulthuis, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203:631–637. doi:10.1002/path.1570
12. Marc D, Dominique JF, Élodie B, et al. Human coronavirus: respiratory pathogens revisited as infectious neuroinvasive, neurotropic, and neurovirulent agents. In: Sunit KS, Daniel R. Neuroviral Infections: RNA Viruses and Retroviruses. Florida Boca Raton: CRC press 2013:93-122.
13. Arabi YM, Balkhy HH, Hayden FG, et al. Middle East Respiratory Syndrome. N Engl J Med 2017, 376:584-594. doi:10.1056/NEJMsr1408795
14. Cabello-Verrugio C, Morales MG, Rivera JC, et al. Renin-Angiotensin System: An Old Player with Novel Functions in Skeletal Muscle. Med Res Rev 2015, 35:437–63. doi:10.1002/med.21343
15. Ding Y, He L, Zhang Q, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol 2004; 203:622- 30. doi:10.1002/path.1560